660 related articles for article (PubMed ID: 25453730)
1. Do dipeptidyl peptidase IV (DPP-IV) inhibitors cause heart failure?
Clifton P
Clin Ther; 2014 Dec; 36(12):2072-2079. PubMed ID: 25453730
[TBL] [Abstract][Full Text] [Related]
2. Assessment of the Risk of Hospitalization for Heart Failure With Dipeptidyl Peptidase-4 Inhibitors, Saxagliptin, Alogliptin, and Sitagliptin in Patients With Type 2 Diabetes, Using an Alternative Measure to the Hazard Ratio.
Kaneko M; Narukawa M
Ann Pharmacother; 2017 Jul; 51(7):570-576. PubMed ID: 28622738
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes.
Scheen AJ
Postgrad Med; 2013 May; 125(3):7-20. PubMed ID: 23748503
[TBL] [Abstract][Full Text] [Related]
4. Dipeptidyl peptidase-4 inhibitors and heart failure: a meta-analysis of randomized clinical trials.
Monami M; Dicembrini I; Mannucci E
Nutr Metab Cardiovasc Dis; 2014 Jul; 24(7):689-97. PubMed ID: 24793580
[TBL] [Abstract][Full Text] [Related]
5. An update on the 'gliptins'.
Drug Ther Bull; 2016 Dec; 54(12):138-141. PubMed ID: 27979881
[TBL] [Abstract][Full Text] [Related]
6. Is the Use of DPP-4 Inhibitors Associated With an Increased Risk for Heart Failure? Lessons From EXAMINE, SAVOR-TIMI 53, and TECOS.
Schernthaner G; Cahn A; Raz I
Diabetes Care; 2016 Aug; 39 Suppl 2():S210-8. PubMed ID: 27440835
[No Abstract] [Full Text] [Related]
7. Cardiovascular safety signals with dipeptidyl peptidase-4 inhibitors: A disproportionality analysis among high-risk patients.
Baksh SN; McAdams-DeMarco M; Segal JB; Alexander GC
Pharmacoepidemiol Drug Saf; 2018 Jun; 27(6):660-667. PubMed ID: 29655237
[TBL] [Abstract][Full Text] [Related]
8. SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO.
Lingvay I
Endocr Pract; 2017 Jul; 23(7):831-840. PubMed ID: 28332871
[TBL] [Abstract][Full Text] [Related]
9. Dipeptidyl peptidase-4 inhibitors and heart failure: Analysis of spontaneous reports submitted to the FDA Adverse Event Reporting System.
Raschi E; Poluzzi E; Koci A; Antonazzo IC; Marchesini G; De Ponti F
Nutr Metab Cardiovasc Dis; 2016 May; 26(5):380-6. PubMed ID: 27067162
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular events and all-cause mortality in patients with type 2 diabetes treated with dipeptidyl peptidase-4 inhibitors: An extensive meta-analysis of randomized controlled trials.
Mannucci E; Nreu B; Montereggi C; Ragghianti B; Gallo M; Giaccari A; Monami M;
Nutr Metab Cardiovasc Dis; 2021 Sep; 31(10):2745-2755. PubMed ID: 34364771
[TBL] [Abstract][Full Text] [Related]
11. Early and Chronic Dipeptidyl-Peptidase-IV Inhibition and Cardiovascular Events in Patients With Type 2 Diabetes Mellitus After an Acute Coronary Syndrome: A Landmark Analysis of the EXAMINE Trial.
Sharma A; Cannon CP; White WB; Liu Y; Bakris GL; Cushman WC; Zannad F
J Am Heart Assoc; 2018 May; 7(11):. PubMed ID: 29769203
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular Safety of Incretin-Based Therapies in Type 2 Diabetes: Systematic Review of Integrated Analyses and Randomized Controlled Trials.
Mannucci E; Monami M
Adv Ther; 2017 Jan; 34(1):1-40. PubMed ID: 27844335
[TBL] [Abstract][Full Text] [Related]
13. Insights from cardiovascular outcome trials with novel antidiabetes agents: what have we learned? An industry perspective.
Hirshberg B; Katz A
Curr Diab Rep; 2015 Nov; 15(11):87. PubMed ID: 26370698
[TBL] [Abstract][Full Text] [Related]
14. No increased risk of hospitalization for heart failure for patients treated with dipeptidyl peptidase-4 inhibitors in Taiwan.
Chang CH; Chang YC; Lin JW; Caffrey JL; Wu LC; Lai MS; Chuang LM
Int J Cardiol; 2016 Oct; 220():14-20. PubMed ID: 27389437
[TBL] [Abstract][Full Text] [Related]
15. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial.
Scirica BM; Braunwald E; Raz I; Cavender MA; Morrow DA; Jarolim P; Udell JA; Mosenzon O; Im K; Umez-Eronini AA; Pollack PS; Hirshberg B; Frederich R; Lewis BS; McGuire DK; Davidson J; Steg PG; Bhatt DL;
Circulation; 2014 Oct; 130(18):1579-88. PubMed ID: 25189213
[TBL] [Abstract][Full Text] [Related]
16. Clinical practice considerations and review of the literature for the Use of DPP-4 inhibitors in patients with type 2 diabetes and chronic kidney disease.
Ramirez G; Morrison AD; Bittle PA
Endocr Pract; 2013; 19(6):1025-34. PubMed ID: 23757605
[TBL] [Abstract][Full Text] [Related]
17. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.
Scirica BM; Bhatt DL; Braunwald E; Steg PG; Davidson J; Hirshberg B; Ohman P; Frederich R; Wiviott SD; Hoffman EB; Cavender MA; Udell JA; Desai NR; Mosenzon O; McGuire DK; Ray KK; Leiter LA; Raz I;
N Engl J Med; 2013 Oct; 369(14):1317-26. PubMed ID: 23992601
[TBL] [Abstract][Full Text] [Related]
18. [The TECOS, EXAMINE and SAVOR studies--how do they differ and what are their outcomes?].
Špinar J; Špinarová L; Vítovec J
Vnitr Lek; 2015 Nov; 61(11):976-83. PubMed ID: 26652787
[TBL] [Abstract][Full Text] [Related]
19. DPP-4 inhibitors and cardiovascular disease in type 2 diabetes mellitus. Expectations, observations and perspectives.
Bonora E; Cigolini M
Nutr Metab Cardiovasc Dis; 2016 Apr; 26(4):273-84. PubMed ID: 27038847
[TBL] [Abstract][Full Text] [Related]
20. [New antihyperglycemic drugs. Examination of cardiovascular outcomes with alogliptin versus standard of care (EXAMINE) and saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR-TIMI 53)].
Gallwitz B; Nitschmann S
Internist (Berl); 2014 Jul; 55(7):859-62. PubMed ID: 24969610
[No Abstract] [Full Text] [Related]
[Next] [New Search]